Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

China: We Are Not A Center For Fake Drugs

By Pharmaceutical Processing | May 26, 2009

BEIJING (AP) — China has been unfairly branded a center of fake drugs, an official with the country’s drug watchdog said, blaming instead some overseas companies that source their raw materials through illegal suppliers. China’s pharmaceutical industry is lucrative but poorly regulated. Chinese manufacturers and other players along the drug supply chain have been blamed in recent years for deaths linked to counterfeit or shoddy medications at home and abroad. “The problem lies in the fact that some overseas companies have an implicit deal with underground factories or illegal manufacturers in China, so the product involved has problems,” Bian Zhenjia, director of the drug safety supervision department under the State Food and Drug Administration, told a press conference. He did not name companies, but he urged foreign companies to be more responsible and to source from legitimate suppliers. Chinese suppliers were blamed last year for the deadly contamination of the blood thinner heparin, which was recalled in the United States after reports of deaths and hundreds of allergic reactions. As many as 81 died. Raw heparin is derived from pig intestines, often processed by small, unregistered businesses in China. China has also recalled drugs and herbal medicines on the domestic market. Counterfeit versions of popular drugs, such as Pfizer Inc.’s Viagra, are widely available. A diabetes drug was pulled in January after it was linked to two deaths in the far western region of Xinjiang. Samples showed the medicine contained six times the normal amount of a chemical ingredient used to lower blood sugar. China’s SFDA counted 329,613 cases of distribution of unlicensed drugs and medical products in 2007, according to the China Daily newspaper.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE